These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 15262831)

  • 1. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.
    Vaziri ND; Liang KH
    Circulation; 2004 Jul; 110(4):419-25. PubMed ID: 15262831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure.
    Vaziri ND; Liang K
    Am J Physiol Renal Physiol; 2004 Nov; 287(5):F1038-43. PubMed ID: 15280162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
    Vaziri ND; Liang K
    Am J Nephrol; 2004; 24(6):606-13. PubMed ID: 15583480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LCAT, ACAT, LDL receptor, and SRB-1 in hereditary analbuminemia.
    Liang K; Vaziri ND
    Kidney Int; 2003 Jul; 64(1):192-8. PubMed ID: 12787409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis.
    Vaziri ND; Sato T; Liang K
    Kidney Int; 2003 May; 63(5):1756-63. PubMed ID: 12675851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome.
    Vaziri ND; Liang K
    Kidney Int; 2002 May; 61(5):1769-75. PubMed ID: 11967026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure.
    Liang K; Kim CH; Vaziri ND
    Am J Physiol Renal Physiol; 2005 Mar; 288(3):F539-44. PubMed ID: 15507547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome.
    Vaziri ND; Liang K; Parks JS
    Am J Physiol Renal Physiol; 2001 May; 280(5):F823-8. PubMed ID: 11292624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, SR-B1, and ACAT in diet-induced syndrome X.
    Roberts CK; Liang K; Barnard RJ; Kim CH; Vaziri ND
    Kidney Int; 2004 Oct; 66(4):1503-11. PubMed ID: 15458444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic tissue sterol regulatory element binding protein 2 and low-density lipoprotein receptor in nephrotic syndrome.
    Kim CH; Kim HJ; Mitsuhashi M; Vaziri ND
    Metabolism; 2007 Oct; 56(10):1377-82. PubMed ID: 17884448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of acyl-CoA: cholesterol acyltransferase in chronic renal failure.
    Liang K; Vaziri ND
    Am J Physiol Endocrinol Metab; 2002 Oct; 283(4):E676-81. PubMed ID: 12217884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Astragalus mongholicus and Angelica sinensis compound alleviates nephrotic hyperlipidemia in rats.
    Li J; Yu L; Li N; Wang H
    Chin Med J (Engl); 2000 Apr; 113(4):310-4. PubMed ID: 11775225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome.
    Liang K; Vaziri ND
    Kidney Int; 1999 Aug; 56(2):621-6. PubMed ID: 10432401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.
    Vaziri ND
    Kidney Int; 2016 Jul; 90(1):41-52. PubMed ID: 27165836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACAT inhibition decreases LDL cholesterol in rabbits fed a cholesterol-free diet. Marked changes in LDL cholesterol without changes in LDL receptor mRNA abundance.
    Krause BR; Pape ME; Kieft K; Auerbach B; Bisgaier CL; Homan R; Newton RS
    Arterioscler Thromb; 1994 Apr; 14(4):598-604. PubMed ID: 8148358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrotic syndrome causes upregulation of HDL endocytic receptor and PDZK-1-dependent downregulation of HDL docking receptor.
    Vaziri ND; Gollapudi P; Han S; Farahmand G; Yuan J; Rahimi A; Moradi H
    Nephrol Dial Transplant; 2011 Oct; 26(10):3118-23. PubMed ID: 21459782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of alteration of hepatic cholesterol metabolism in puromycin-induced nephrotic syndrome in rats.
    Thabet MA; Challa A; Chan JC; Pandak WM; Heuman DM; Vlahcevic ZR
    Kidney Int; 1993 Oct; 44(4):789-94. PubMed ID: 8258956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acyl-coenzyme A: cholesterol- acyl-coenzyme A:1,2-diacylglycerol acyltransferase and phosphatidate phosphorylase activities in liver microsomes from nephrotic rats.
    Agbedana EO; Yamamoto T; Moriwaki Y; Takahashi S; Suda M; Higashino K
    Afr J Med Med Sci; 1996 Dec; 25(4):365-71. PubMed ID: 9532309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of hepatic Acyl CoA: Diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome.
    Vaziri ND; Kim CH; Phan D; Kim S; Liang K
    Kidney Int; 2004 Jul; 66(1):262-7. PubMed ID: 15200432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of hepatic LDL receptor-related protein in nephrotic syndrome: response to statin therapy.
    Kim S; Kim CH; Vaziri ND
    Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E813-7. PubMed ID: 15585592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.